Welcome to our dedicated page for Argenx Se SEC filings (Ticker: ARGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
argenx SE filings document the regulatory record of a foreign private issuer commercializing antibody-based medicines for severe autoimmune diseases. Form 6-K reports furnish press releases, investor presentations, financial results, FDA label updates for VYVGART and VYVGART Hytrulo, and clinical data presentations for programs in myasthenia gravis, CIDP, multifocal motor neuropathy, and related neuromuscular disorders.
The filings also cover annual-report materials filed with Dutch and U.S. regulators, incorporation by reference into Form S-8 registration statements, annual general meeting notices and results, board appointments, remuneration and annual-account votes, and other governance matters. These disclosures provide the formal record for argenx's product sales, pipeline development, capital-market reporting, risk factors, and foreign-issuer status.
Artisan Partners and affiliated entities report beneficial ownership of 2,349,776 American Depositary Shares of Argenx, representing 3.8% of the 61,166,252 ADS outstanding. The filing shows no sole voting or dispositive power; instead the filers report shared voting power of 2,010,189 ADS and shared dispositive power of 2,349,776. The reporting persons are Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership, all organized in Delaware with a principal business address in Milwaukee, WI.
The statement is made on Schedule 13G and includes a joint filing agreement among the reporting persons, and it certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
argenx SE (ARGX) has filed a Form 6-K for June 2025. The filing’s sole purpose is to furnish a press release dated 20 June 2025, attached as Exhibit 99.1 and incorporated by reference into the company’s outstanding Form S-8 registration statements (File Nos. 333-225375, 333-258253 and 333-274721). No financial statements, earnings figures, or transactional details are included in the filing, and the text does not disclose the subject matter of the referenced press release. The document therefore serves an administrative function, ensuring the press release is part of the SEC record and automatically updates the company’s registration statements.